Welcome to your Personalized User Bar. Here, you can manage your account, sign up for newsletters, navigate to site sections, and share interesting content on social networks. You also can receive alerts on upcoming events, new products, or subscription/account activities. Continue reading →
Posted on behalf of Monya Baker. The California Institute of Regenerative Medicine (CIRM) voted on 24 May to accept a new strategic plan which shrinks or eliminates support for basic research, facilities and training, while funneling more of its funds toward clinical development. “The first stage of CIRM was really exploring the field,” said Ellen Feigal, senior vice president of R&D. “The next five years should be one of more focus.” By July 2013, the agency hopes to have two programmes approved for clinical trials in the United States. During the past five years, nearly half of the approximately $1.3 billion awarded by the agency went toward building new research facilities and training and career development. Looking ahead, of the approximately $840 million to be ... Continue reading →
For more than a decade, almost all processed foods in the United States — cereals, snack foods, salad dressings — have contained ingredients from plants whose DNA was manipulated in a laboratory. Regulators and many scientists say these pose no danger. But as Americans ask more pointed questions about what they are eating, popular suspicions about the health and environmental effects of biotechnology are fueling a movement to require that food from genetically modified crops be labeled, if not eliminated. Labeling bills have been proposed in more than a dozen states over the last year, and an appeal to the Food and Drug Administration last fall to mandate labels nationally drew more than a million signatures. There is an iPhone app: ShopNoGMO. The most closely ... Continue reading →
NEW YORK (AP) — Onyx Pharmaceuticals Inc. shares rose Thursday after a Bernstein Research analyst started covering the stock with an "Outperform" rating, saying he thinks the company's blood cancer drug candidate will reach $1 billion in annual sales by 2016. THE SPARK: Analyst Geoffrey Porges said he thinks that the drug, Kyprolis, will win broad marketing approval from regulators in 2014. He said sales could reach $2 billion annually by 2020. THE BIG PICTURE: The South San Francisco, Calif., company's annual revenue in 2011 was $477.2 million, so that would be a big increase. Onyx sells a liver and kidney cancer drug, Nexavar, through a partnership with German drugmaker Bayer AG. Kyprolis, or carfilzomib, is an experimental treatment for multiple myeloma, a type of ... Continue reading →
(San Francisco Business Times subscription required.) Three years after outsiders worried that Roche’s $47 billion buyout would downgrade the company’s revered research group, the Food and Drug Administration next month could give the legendary South San Francisco biotech company its third drug approval in the past 10 months. What’s more, Genentech expects to file later this year for FDA approval of another highly targeted and less toxic cancer-fighting drug. But it isn’t only drugs that were already in the clinic at the time of the Roche deal that have Genentech scientists excited. Continue reading →
